What is the recommended management for a patient with non‑alcoholic fatty liver disease (NAFLD)?

Management of Non-Alcoholic Fatty Liver Disease (NAFLD)

The cornerstone of NAFLD management is risk stratification by fibrosis stage using non-invasive tests (FIB-4 or NAFLD fibrosis score), followed by risk-appropriate interventions focused on weight loss through lifestyle modification, cardiovascular risk reduction, and consideration of specific pharmacotherapy based on fibrosis severity. 1

Initial Risk Stratification: The Critical First Step

All patients with suspected or confirmed NAFLD must undergo fibrosis risk assessment using validated non-invasive tests - specifically FIB-4 score or NAFLD fibrosis score - as these have high negative predictive value for excluding advanced fibrosis 1, 2. This is the pivotal decision point that determines all subsequent management.

Important Caveat on Screening

Do not rely solely on abnormal liver enzymes to identify NAFLD - many patients with significant fibrosis have normal transaminases. However, persistently unexplained abnormal liver tests should always trigger investigation 1. Similarly, incidental hepatic steatosis on ultrasound should prompt fibrosis risk assessment 1.

Management Based on Fibrosis Risk

Low-Risk Patients (FIB-4 <1.3, LSM <8.0 kPa, or F0-F1 on biopsy)

Manage in primary care with focus on lifestyle interventions and cardiovascular risk reduction 1, 2:

• Weight loss is the primary therapeutic target: Aim for 7-10% body weight reduction through caloric restriction
• Mediterranean diet specifically: Daily vegetables, fresh fruit, high-fiber unsweetened cereals, nuts, fish or white meat, olive oil; minimize simple sugars and red/processed meats 2
• Physical activity: Moderate aerobic exercise regardless of weight status 3
• Alcohol restriction: Even low alcohol intake (9-20g daily) doubles risk of adverse liver outcomes in NAFLD patients 2
• Reassess fibrosis risk every 3 years using non-invasive tests 1

No liver-specific pharmacotherapy is indicated for low-risk patients - treatment targets cardiometabolic health 2.

Indeterminate Risk Patients

Offer additional discriminatory testing (transient elastography or Enhanced Liver Fibrosis [ELF] test) or refer to hepatology for further evaluation 1, 2. These patients require more definitive risk stratification before determining management pathway.

High-Risk Patients (Advanced Fibrosis or Cirrhosis)

Mandatory referral to hepatology for multidisciplinary management 1:

• All lifestyle interventions as above, intensified
• Confirmation of diagnosis and fibrosis stage
• Consider liver biopsy if:
  • Diagnostic uncertainty exists
  • Staging remains inconclusive
  • Patient being considered for NASH drug therapies or clinical trials 1
• Surveillance for hepatocellular carcinoma and varices if cirrhosis present 1
• Aggressive management of metabolic and cardiovascular risk factors

Pharmacotherapy Considerations

For Patients with Type 2 Diabetes and NASH

GLP-1 receptor agonists (particularly dulaglutide) and pioglitazone have demonstrated histologic improvement in NASH 4, 5. The combination of tofogliflozin with pioglitazone shows particular promise 3.

For Patients with Obesity

Consider weight loss medications, particularly GLP-1 receptor agonists, or bariatric surgery for appropriate candidates 4, 5. These interventions can reverse NASH and improve fibrosis.

Agents Under Investigation

While no FDA-approved NAFLD-specific medications currently exist 4, promising agents in development include FXR agonists, PPAR agonists, and FGF analogues 6, 7. Vitamin E and pioglitazone are considered by some guidelines for biopsy-proven NASH 7.

Critical Management Principles

Cardiovascular disease, not liver disease, is the leading cause of death in NAFLD patients (before cirrhosis develops) 2, 8. Therefore, aggressive cardiovascular risk modification is paramount and takes precedence in non-cirrhotic patients.

Advanced liver fibrosis is the key prognostic marker for liver-related outcomes and overall mortality 8. This is why risk stratification by fibrosis stage drives all management decisions.

Common Pitfalls to Avoid

• Don't wait for abnormal liver enzymes - they are insensitive for detecting significant disease 1
• Don't treat simple steatosis as a target - its presence is merely a biomarker for potential steatohepatitis with fibrosis 2
• Don't forget that lean individuals can have NAFLD - they often have unfavorable metabolic profiles with visceral adiposity despite normal BMI 2
• Don't overlook the bidirectional relationship with metabolic syndrome - aggressively screen patients with Type 2 diabetes or metabolic syndrome for liver fibrosis 1, 4

Multidisciplinary Approach

Optimal NAFLD care requires coordination between primary care, endocrinology (for diabetes management), and hepatology 2, 4. This is particularly critical for patients with obesity, diabetes, cardiovascular disease, and significant fibrosis, where complexity demands integrated management.